Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Aluwini S, et al. Among authors: schimmel e. Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968359 Clinical Trial.
Hypofractionation in glioblastoma multiforme.
Hulshof MC, Schimmel EC, Andries Bosch D, González González D. Hulshof MC, et al. Among authors: schimmel ec. Radiother Oncol. 2000 Feb;54(2):143-8. doi: 10.1016/s0167-8140(99)00183-8. Radiother Oncol. 2000. PMID: 10699477 Clinical Trial.
Do prostate cancer patients want to choose their own radiation treatment?
van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Leer JW. van Tol-Geerdink JJ, et al. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1105-11. doi: 10.1016/j.ijrobp.2006.07.001. Epub 2006 Sep 11. Int J Radiat Oncol Biol Phys. 2006. PMID: 16965869
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Among authors: schimmel e. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.
Correction to Lancet Oncol 2015; 16: 274.
Aluwini S, Pos F, Schimmel E. Aluwini S, et al. Among authors: schimmel e. Lancet Oncol. 2015 Mar;16(3):e105. doi: 10.1016/S1470-2045(15)70096-3. Lancet Oncol. 2015. PMID: 25752558 No abstract available.
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. Incrocci L, et al. Among authors: schimmel e. Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339116 Clinical Trial.
72 results